1. Home
  2. KTCC vs RNTX Comparison

KTCC vs RNTX Comparison

Compare KTCC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KTCC
  • RNTX
  • Stock Information
  • Founded
  • KTCC 1969
  • RNTX 2001
  • Country
  • KTCC United States
  • RNTX United States
  • Employees
  • KTCC N/A
  • RNTX N/A
  • Industry
  • KTCC Electrical Products
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KTCC Technology
  • RNTX Health Care
  • Exchange
  • KTCC Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • KTCC 34.0M
  • RNTX 40.3M
  • IPO Year
  • KTCC N/A
  • RNTX N/A
  • Fundamental
  • Price
  • KTCC $2.76
  • RNTX $1.56
  • Analyst Decision
  • KTCC
  • RNTX
  • Analyst Count
  • KTCC 0
  • RNTX 0
  • Target Price
  • KTCC N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • KTCC 30.1K
  • RNTX 33.4K
  • Earning Date
  • KTCC 08-12-2025
  • RNTX 08-13-2025
  • Dividend Yield
  • KTCC N/A
  • RNTX N/A
  • EPS Growth
  • KTCC N/A
  • RNTX N/A
  • EPS
  • KTCC N/A
  • RNTX N/A
  • Revenue
  • KTCC $483,941,000.00
  • RNTX N/A
  • Revenue This Year
  • KTCC N/A
  • RNTX N/A
  • Revenue Next Year
  • KTCC N/A
  • RNTX N/A
  • P/E Ratio
  • KTCC N/A
  • RNTX N/A
  • Revenue Growth
  • KTCC N/A
  • RNTX N/A
  • 52 Week Low
  • KTCC $2.21
  • RNTX $1.35
  • 52 Week High
  • KTCC $6.14
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • KTCC 44.86
  • RNTX N/A
  • Support Level
  • KTCC $2.83
  • RNTX N/A
  • Resistance Level
  • KTCC $3.06
  • RNTX N/A
  • Average True Range (ATR)
  • KTCC 0.14
  • RNTX 0.00
  • MACD
  • KTCC -0.03
  • RNTX 0.00
  • Stochastic Oscillator
  • KTCC 0.00
  • RNTX 0.00

About KTCC Key Tronic Corporation

Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: